3:30 PM - 3:45 PM (PDT), Tuesday, June 14, 2022
PepLib is rethinking peptide drug discovery. PepLib’s platform, powered by Peptide Information Compression Technology (PICT), is capable of high-sensitivity and high-specificity drug mining for a broad spectrum of targets, including membrane-proteins, such as GPCR and ion channels, and directly on cell-lines. Intelligently designed, individually isolated and packed peptides in HTS compatible format breaks through traditional limitations of peptide screening platforms, extending capabilities beyond binding assays to cell-based functional assay. PepLib has validated the efficiency of the platform in over 40 successful screenings on dozens of molecular targets and cell-lines, through external partnerships and internal development programs in metabolic diseases, internal medicine, oncology, pain, and anti-infectives.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Kinase inhibitor
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Senior Vice President, Business Development
Zonsen PepLib BioTech Ltd.